Netherlands Cancer Institute

What Netherlands Cancer Institute does

The Netherlands Cancer Institute (NKI), founded on October 10, 1913, and headquartered in Amsterdam, is a private non-profit research organization that operates across the full spectrum of cancer science — from fundamental laboratory research through translational work to clinical research and treatment. It employs approximately 600 scientists supported by around 300 scientific and administrative staff, representing roughly 55 nationalities, and is physically co-located with the Antoni van Leeuwenhoek Hospital, providing an integrated bench-to-bedside research environment. Over its 110+ year history, NKI has produced more than 9,151 peer-reviewed publications and has become anchored in multiple (inter)national scientific networks.

NKI's productized output centers on a portfolio of validated AI tools for oncology. Key assets include ARTIMES, an AI model that evaluates treatment response in pleural mesothelioma by volumetric analysis of CT scans (published in The Lancet Oncology, validated against 11,000+ scans from 121 hospitals); PARM, a deep learning model under the Oncode Institute's PERICODE project that predicts regulatory impact of genetic mutations on human promoters with roughly 1,000x greater compute efficiency than comparable models (published in Nature); and plasmaCHORD, a co-developed machine learning tool with Johns Hopkins Kimmel Cancer Center that improves liquid biopsy mutation identification from ~50% to 83%. The institute also actively collaborates on the DELFI whole-genome cfDNA fragmentomics platform for cancer detection and monitoring.

NKI's business model is non-commercial: it is funded through government research grants, charitable foundations, competitive national and international funding, and industry collaborations. Its go-to-market motion is community-led, distributing outputs through peer-reviewed publications, international conferences, and strategic academic and industry partnerships. Patient-facing care is delivered through the associated Antoni van Leeuwenhoek hospital. Customer relationships are primarily institutional — academic research groups, biotechnology and pharmaceutical companies, and other healthcare providers — while its broader societal constituency is cancer patients receiving advanced treatments, precision oncology, and clinical trial access at the institute.

Name

Netherlands Cancer Institute

Legal name

Netherlands Cancer Institute

Website

https://nki.nl

Company type

Private

Founded year

1913

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

The Netherlands Cancer Institute (NKI) is an Amsterdam-based, non-profit cancer research organization founded in 1913 that conducts fundamental, translational, and clinical oncology research with roughly 600 scientists, while developing validated AI diagnostic tools (including ARTIMES, PARM, and plasmaCHORD) and partnering globally with academic and industry collaborators.

Ownership category

akta.pro rank

Product category

Cancer Research and Clinical Oncology Services

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Health Services (8000)

akta.pro primary industry

Clinical Research & Trial Central Laboratories (HLAFAMAL)

akta.pro secondary industries

Medical Oncology (HLAKAFAB), Anatomic Pathology (Histopathology & Cytopathology) (HLAFAMAA)

Keywords

• Cancer research
• Clinical oncology
• Precision medicine
• Translational research
• AI diagnostics

Headquarters

HQ city

Amsterdam

HQ country

Netherlands

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

1. Research Funding & Grants: The NKI operates as a non-profit research institute funded through government research grants, competitive funding from national and international agencies, charitable foundations, and industry collaborations.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

The Netherlands Cancer Institute (NKI) is a non-profit cancer research institute that conducts fundamental, translational, and clinical cancer research. It develops AI-driven diagnostic tools (such as ARTIMES for tumor volumetrics and plasmaCHORD for liquid biopsy), provides clinical care through the Antoni van Leeuwenhoek hospital, and collaborates with academic and industry partners on biomarker discovery, drug development, and precision oncology.

Product overview

The Netherlands Cancer Institute (NKI) is a leading cancer research institute that develops AI-powered diagnostic tools and research platforms. Key offerings include ARTIMES, an AI model for volumetric tumor assessment in pleural mesothelioma, and PARM, a deep learning model for predicting gene regulatory mutations. NKI also collaborates on the DELFI whole-genome cfDNA platform for cancer detection and monitoring. The institute operates various research groups, facilities, and platforms covering the full spectrum from fundamental research to clinical research, with approximately 600 scientists working across multiple disciplines.

Differentiator

Problem solved

Functional benefit

Products and services

• ARTIMES (AI-assisted Volumetric Response Criteria)
• PARM (Promoter Activity Regulatory Model)
• plasmaCHORD
• DELFI Whole-Genome cfDNA Platform
• Clinical Cancer Care Services
• Cancer Research Collaboration Services

Quantifiable outcome

• ARTIMES AI model outperforms expert human clinicians in accuracy and consistency for pleural mesothelioma tumor assessment
• +2 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature3 records

Partnerships

Six partnerships are on record, tiered core and major.

• Johns Hopkins Kimmel Cancer CentercoreStrategic or Co-development Partner · 1 June 2026Collaborative development of plasmaCHORD machine learning tool for liquid biopsy diagnostics. The partnership involves analyzing cell-free DNA fragmentation patterns to improve mutation identification accuracy in cancer diagnostics, with the tool already deployed within Johns Hopkins Molecular Tumor Board.
• Vanderbilt UniversitymajorStrategic or Co-development Partner · 1 June 2026Collaborative involvement in the development and validation of plasmaCHORD machine learning tool for liquid biopsy diagnostics, working alongside Johns Hopkins and LabCorp.
• LabCorpmajorStrategic or Co-development Partner · 1 June 2026Collaborative involvement in plasmaCHORD machine learning tool development for liquid biopsy diagnostics, contributing to improved mutation identification accuracy in clinical settings.
• DELFI DiagnosticsmajorStrategic or Co-development Partner · 1 April 2026Academic collaboration on whole-genome cfDNA fragmentomics platform for cancer detection and monitoring. NKI researchers co-present findings at AACR 2026 including the DOLPHIN study on colorectal cancer treatment response monitoring in approximately 500 patients.
• MRM HealthcoreStrategic or Co-development Partner · 1 December 2025Strategic partnership with Belgian microbiome company MRM Health to develop microbiome-based therapeutics for cancer immunotherapy. The collaboration aims to enhance the effectiveness of immune checkpoint inhibitors and explore broader applications beyond oncology, leveraging MRM's CORAL platform and Professor Emile Voest's expertise in tumour microbiome research.
• Oncode InstitutecoreStrategic or Co-development Partner · 1 December 2025Collaboration with the Oncode Institute on the PERICODE project (seven research groups) for the development of PARM deep learning model and microbiome-based therapeutics research. The partnership focuses on predicting gene regulation and developing novel cancer diagnostics and therapies.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Memorial Sloan Kettering Cancer Center: Major US cancer research and treatment center with integrated basic, translational, and clinical research programs. Highly comparable to NKI in combining a research institute with a dedicated cancer hospital.
• Dana-Farber Cancer Institute: Harvard-affiliated cancer research and treatment institute with strong translational pipelines and significant AI/biomarker research activity, closely analogous to NKI's integrated research-care model.
• German Cancer Research Center (DKFZ): Europe's largest biomedical research institute focused on cancer, with broad translational and computational oncology programs and public funding — a direct functional peer to NKI within the European ecosystem.
• Karolinska Institutet: Leading Swedish medical research university with major cancer research programs, translational pipelines, and clinical trial infrastructure; comparable in mission and European public-research orientation.
• Francis Crick Institute: Large London-based biomedical discovery institute with significant cancer biology research, AI/computational biology, and translational programs — highly analogous operating model and scale.
• Broad Institute: MIT/Harvard-affiliated genomics and biomedical research institute with leading AI for genomics and large-scale translational programs; directly comparable in applying AI/ML to oncology and genomics at scale.
• Wellcome Sanger Institute: UK-based genomics and cancer research institute with large-scale sequencing, computational biology, and translational programs; analogous scale and mission within the European public-research landscape.

Broad incumbents

• MD Anderson Cancer Center: One of the largest dedicated cancer centers globally, with deep investment in AI-driven oncology, genomics, and clinical trials. Broader in scale but operates a similar end-to-end research-to-care mandate.

Regional players

• Vall d'Hebron Institute of Oncology (VHIO): Spain's leading oncology research institute with translational and clinical research programs; comparable in mission and structure but operating primarily in a different Southern European ecosystem.
• Gustave Roussy Institute: Major French comprehensive cancer center integrating research and clinical care; comparable integrated model but anchored in France rather than the Netherlands.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/watch?v=Y1ogLuGzpnY
• Xx.com/nki_nl

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Netherlands Cancer Institute